CoreRx, Inc. Unveils SuiteView - Plans for Novel View into GMP Manufacturing Suites
CoreRx, Inc., a Tampa-based pharmaceutical development company, which has already begun a major expansion of its new headquarters at 14205 Myerlake Circle, today announces the addition of SuiteView to its service offerings.
CoreRx Continues to Increase Staff - Adds BD Director
CoreRx has appointed William Beck as Director, Business Development, covering the Northeast. Mr. Beck will be responsible for all business development activities in support of the company’s strategic growth and development plans for this region.
CoreRx Continues to Expand - Adds Additional Capabilities
CoreRx, a leader in early drug contract development, has expanded manufacturing capabilities to include the OYSTAR Manesty FLEXITAB, A fully automated, single station tablet press with a multi-layer tablet function, giving it the unique capacity to produce three-layer tablets using a minimal amount of material. Its variable punch displacement and dwell time can be set to simulate compression on any rotary press using compression forces up to100kN.
CoreRx™ has Four Employees Named as Assistant Professors at USF’s School of Pharmacy
Todd Daviau, Matt Greene, Adam Lambert and Brian McMillan given four year appointments to begin teaching this inaugural school year
(Tampa, FL; 15 August 2011) – CoreRx, a leader in early drug development services, today announced the appointments of Todd Daviau, Matt Greene, Adam Lambert and Brian McMillan to the Faculty of the School of Pharmacy at the University of South Florida, as Assistant Professors.
CoreRx Named to Tampa’s 2011 Fast 50
CoreRx, fast becoming a world-recognized leader in early drug contract development, was announced today as one of Tampa Bay’s Fast 50 companies. The Tampa Bay Business Journal’s Fast 50 is a list of the fastest growing privately held companies in Tampa Bay over a span of three years. Last year, CoreRx was recognized as the 6th fastest growing company in the Tampa Bay region.
CoreRx Boosts OSD Capabilities
CoreRx (AAPS Booth 1701) has expanded its oral solid dosage form development and manufacturing capabilities. The company is increasing its capabilities for oral controlled release, and multi-layer dosage forms with the addition of new capsule-fillers, a new high-speed tablet press, and two new V-shell blenders (15 cu. ft., and 30 cu. ft.). This expansion will enable CoreRx to increase its offerings in development and manufacturing services in its new Largo, FL facility and complements the company’s existing oral dosage form development and manufacturing capabilities.
CoreRx Expands Capabilities in GMP Manufacturing
CoreRx, a premier contract development and manufacturing organization supporting the pharmaceutical industry, has complemented existing manufacturing capacities by expanding single-batch blending size capabilities with the acquisition of a 15 cu. ft. and 30 cu. ft. V-blender, and increasing capsule and tablet production by purchasing an automated encapsulator with a rate of 125,000 capsules/hour and an instrumented tablet press with rate of 175,000 tablets/hour. The company has also added a solvent-capable 36 inch coating pan. In addition, the company has added 4,000 additional sq feet to its GMP manufacturing area to include three more GMP manufacturing suites, bringing its total to five.
